Albert Assad, M.D
Incyte Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Albert Assad, M.D as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04551066 · To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)Incyte Corporation · terminated · Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis · study director
- Ph3NCT04551053 · To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte Corporation · terminated · Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis · study director
- Ph1/Ph2NCT01858883 · Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsIncyte Corporation · completed · Solid Tumors, Pancreatic Cancer · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.